Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (15)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Zidan, J.
Right arrow Articles by Kuten, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zidan, J.
Right arrow Articles by Kuten, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 12:227-229, 2001
© 2001 European Society for Medical Oncology

research-article

Octreotide in the treatment of severe chemotherapy-induced diarrhea

J. Zidan1,2,, N. Haim2,3, A. Beny2,3, M. Stein2,3, E. Gez2,3 and A. Kuten2,3

1Oncology Unit, Sieff Government Hospital, Safed
2Faculty of Medicine. Technion Israel Institute of Technology
3Oncology Department, Ramban Medical Center, Haifa, Israel

J Zidan, MD Oncology Unit, Sieff Government Hospital POB 1008 Safed 13100 Israeljzidan{at}internet-zahav.net.il

BACKGROUND:: Chemotherapy-induced diarrhea (CID) is a common side effect of a number of chemotherapeutic agents. Conventional therapy for severe CID with opioids or loperamide is moderately effective. A prospective trial was conducted using octreotide acetate for treatment of severe CID refractory to loperamide.

PATIENTS AND METHODS:: Thirty-two patients with grade 2 and 3 CID refractory to loperamide were treated with octreotide at a dosage of 100 µg subcutaneously 3 x/day for three days followed by 50 µg 3 x/day for three days. Previous chemotherapy consisted of regimens containing fluorouracil, leucovorin, CPT-11, cyclophosphamide, methotrexate and cisplatin. Primary tumors were colorectal (n = 23), gastric (n = 3), and other cancers (n = 6).

RESULTS:: Complete resolution of diarrhea was obtained in 30 of 32 patients (94%); 5 within 24 hours, 14 within 48 hours, and 11 within 72 hours of treatment. Nineteen patients were treated as outpatients. Thirteen were hospitalized for a median of three days. Response was unaffected by age, gender, performance status, previous chemotherapy or primary tumor site. No side effects related to octreotide were observed.

CONCLUSIONS:: Octreotide 100 µg subcutaneously 3 x/day for three days is an effective, safe treatment for CID given primarily or as a second-line therapy after loperamide failure.

octreotide, refractory chemotherapy-induced diarrhea, treatment


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
G. Brandi, J. Dabard, P. Raibaud, M. Di Battista, C. Bridonneau, A. M. Pisi, A. M. M. Labate, M. A. Pantaleo, A. De Vivo, and G. Biasco
Intestinal Microflora and Digestive Toxicity of Irinotecan in Mice
Clin. Cancer Res., February 15, 2006; 12(4): 1299 - 1307.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.